Prostaglandin E2 (PGE 2 ), a major product of cyclooxygenase -2 (COX-2), acts as an immunomodulator at the maternal-fetal interface during pregnancy. It exerts biological function through interaction with E-prostanoid (EP) receptors localized to the placenta.
INTRODUCTION
Inflammation has an important role in the pathophysiology of several common and serious pregnancy disorders that are each associated with adverse outcomes and compromised placental function. The inflammatory responses observed during pregnancy are complex and the result is often dependent on the timing, severity, and type of stimulus. An inflammatory response can be triggered by a wide variety of pathological stimuli, including hypoxia, infection, tissue damage, trauma and cellular stress (Bloise et al., 2013; Guo et al., 2010) . It is increasingly clear that different stimuli can induce alternative patterns of inflammatory molecules thereby invoking different regulatory patterns of gene expression (Ho and Piquette-Miller, 2006) .
Studies of placental cells and tissue in vitro document their responsiveness to
inflammatory stimuli with increased production of cytokines, chemokines, and prostaglandins (PG) (Keelan et al., 2003) . PGs are potent mediators of immune responses (Betz and Fox, 1991; Roper and Phipps, 1994; Snijdewint et al., 1993) and inflammation (Gilroy et al., 1999; Trebino et al., 2003) . They play a role in many aspects of pregnancy including maternal-fetal tolerance, parturition, and innate immunity. Prostaglandin E2 (PGE 2 ) is the predominant PG produced by the placenta (Myatt, 1990) . As a result, levels at the placental interface are likley higher than in the peripheral circulation. PGE 2 is derived from arachidonic acid (AA) via the activities of cyclooxygenase-2 (COX-2). The effects of PGE 2 are facilitated by specific-membrane bound G-protein coupled EP receptors (EP1-4), which each have distinct signal transduction profiles and often differing cellular actions (Hata and Breyer, 2004) .
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This article has not been copyedited and formatted. The final version may differ from this version. The activation of COX-2 affects the ATP binding cassette (ABC) transporters, multidrug resistance protein (MDR) 1 (P-glycoprotein, Pgp; Gene: ABCB1), multidrug resistance-associated protein (MRP) 1 (Gene: ABCC1), and breast cancer resistance protein (BCRP; Gene: ABCG2) (Liu et al., 2010; Surowiak et al., 2008) , which play important roles in extruding drugs and xenobiotics out of cells. COX-2 up-regulates the expression and activity of Pgp and BCRP in several cell types (Fantappie et al., 2002; Patel et al., 2002) . Furthermore, specific COX-2 inhibitors, such as celecoxib and NS398, block the COX-2-mediated increase in Pgp and BCRP, suggesting that PGE 2 may be implicated in this response (Arico et al., 2002; Arunasree et al., 2008; Ko et al., 2008; Patel et al., 2002; Roy et al., 2010; Zatelli et al., 2007; Zrieki et al., 2008) .
Pgp and BCRP are the most abundant ATP Binding Cassette (ABC) efflux transporters on the apical brush-border membrane of the placenta. These proteins pump compounds back into the maternal circulation and are generally believed to have a protective role (Ceckova-Novotna et al., 2006; Mao, 2008) . However, it's easy to see how problems could arise if they were to prevent drug delivery to the fetus where the medication was intended to have a therapeutic effect. In either instance, changes in Pgp and/or BCRP expression in placenta could effect fetal drug exposure.
The functional expression of Pgp and BCRP can be up or down regulated by exposing placental cells to various inflammatory agents. For example, acute inflammation, such as that mediated by microbial products like LPS, are known to down regulate the expression of several placental transporters, including Pgp (Bloise et al., 2013; Chen et al., 2005; Petrovic et al., 2007; Petrovic et al., 2008; Wang et al., 2005) .
On the other hand, chronic, sub-lethal exposure to LPS had no effect on overall
This article has not been copyedited and formatted. The final version may differ from this version. placental Pgp activity (Bloise et al., 2013) . In other examples of chronic inflammation, such as that observed in subjects with rheumatoid arthritis, Pgp expression is increased (Dumoulin et al., 1997; Llorente et al., 2000) . We previously documented up-regulation of placenta Pgp and BCRP expression in the presence of histological chorioamnionitis (Mason et al., 2011) . Taken together, the findings suggest there are many interactive and reactive mediators of inflammation that can alter these transporters in the placenta.
To date, studies have primarily focused on the effects of proinflammatory cytokines (Evseenko et al., 2007; Ho and Piquette-Miller, 2006) . PGs are released by the actions of proinflammatory cytokines. It has been shown that IL-1β, IL-6, TNFα, and IL-8, directly stimulate PGE 2 production by cells obtained from term placenta (Furuta et al., 2000) . Surprisingly. there is no information on the effects of PGE 2 on ABC efflux transporters in the placenta.
In the present investigation, we tested the hypothesis that PGE 2 increases Pgp and BCRP expression and activity in placental cells via distinct EP receptor signaling pathways. Identification of these signaling pathway(s) could provide important information about mechanisms of inflammation on transporter regulation and facilitate the development of strategies to manipulate Pgp and BCRP expression levels via EP receptor inhibition.
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MATERIALS AND METHODS

Materials
The PG receptor antagonists 8-chloro-dibenz [b,f] [1,4]oxazepine-10(11H)-carboxy-(2-acetyl)hydrazide (SC-19220), 6-isopropoxy-9-oxoxanthene-2-carboxylic acid , and N- [[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl) propenenitrile and (E,E,Z,E)-3-Methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid (SR 11302) was from Caymen Chemical (Ann Arbor, MI) and Tocris Bioscience (R&D Systems, Minneapolis, MN), respectively. The antibody against BCRP (clone BXP21) was purchased from EMD Millipore (Billerica, MA). All receptor antagonists were dissolved in DMSO as 10 mM stock solutions and stored at -20ºC; PGE 2 (1 mg/ml) was dissolved in ethanol. The concentration of DMSO and EtOH after the dilution of compounds to their final concentrations was 0.1% and 0.5%, respectively. Lipofectamine™ 2000, pNF-κB-Luc plasmid, and pAP1-Luc plasmid were purchased from Life Technologies (Carlsbad, CA). The Dual-Luciferase® Reporter Assay System was purchased from Promega (Madison, WI).
Cell Culture
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This article has not been copyedited and formatted. The final version may differ from this version. and spun for 20 min at 1200 × g. Cells between the 40-50% Percoll bands were collected and plated at a density of 6 × 10 6 cells on a 60 mm 2 petri dishes. The cells were grown in M199 media, supplemented with 10% FCS, EGF (10 ng/ml), insulin (5 ng/ml), transferrin (10ng/ml), sodium selenite (0.2 nM), and penicillin/streptomycin (100 U/ml) in a 95% air/5% CO 2 humidified atmosphere at 37°C. After 24h in culture, the cells were washed with phosphate-buffered saline, and renewed with media containing 10% FCS and nystatin.
This article has not been copyedited and formatted. The final version may differ from this version. The purity of the isolated cells was determined by immunofluorescent staining using anti-cytokeratin 7 (C7) and anti-vimentin (vim) antibodies. A proportion of ≥ 90%
C7-positive cells (cytotrophoblasts) was considered to be of sufficient purity. Primary trophoblasts from eight different placentas were used for the regulatory experiments, and the data generated were pooled and analyzed collectively.
Assessment of cytotrophoblast cell biochemical differentiation
The β subunit of hCG is produced by terminally differentiated syncytiotrophoblast and was measured as an indicator of cytotrophoblast differentiation in culture after their isolation from term placenta. Culture medium was collected at 24, 48, 72, 96, and 120h of cytotrophoblast cell culture, and stored in aliquots at −80°C.
β -hCG was measured by ELISA following the manufacturer's instructions (DRG International, Springfield, NJ).
PGE 2 Measurements
Cells were cultured in their respective phenol-red free, charcoal stripped FBS media for 24h. Cytotrophoblasts were cultured for 4 days at which point media was replaced and collected after 24h. The PGE 2 concentration in the media was then determined using a PGE 2 ELISA kit (Thermo Fisher Scientific, Rockford, IL) following the manufacturer's instructions. The sensitivity of the kit was 15.6 pg/mL, and the intraand inter-assay coefficients of variation were less than 10%. PGE 2 concentrations were calculated using a 4 parameter logistic curve fitting program in GraphPad Prism 6.
Treatment
To examine the effect of PGE 2 on Pgp and BCRP transporter expression, cells were cultured in their respective phenol-red free medium supplemented with 10% charcoal/dextran-stripped FBS for 24h. Primary trophoblasts were cultured for 4-5 days
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This article has not been copyedited and formatted. The final version may differ from this version. treatment. In consecutive studies, cells were exposed to an EP3 receptor agonist (Sulprostone, 10 µM) or an EP1 receptor agonist (17-phenyltrinor PGE 2 ) for 24h prior to RNA isolation. Finally, Jar cells were treated with BAY-110782 (10 µM) and SR 11302
(10 µM) for 1h prior to the addition of PGE 2 . Pgp and BCRP mRNA expression was determined at 24h.
RNA Isolation and Purification
Total cellular RNA was isolated from the cells and purified using the RNeasy Mini kit according to manufacturer's instructions. Total RNA concentration was determined by ultraviolet (UV) spectroscopy at 260nm and RNA integrity and purity confirmed by 260/280 ratio (>1.8) and separation on a 1% agarose gel followed by visualization with ethidium bromide.
Real Time Quantitative RT-PCR
Primer sequences for both Pgp and BCRP amplifications were previously described (Mason et al., 2011) . 18s rRNA was used to normalize mRNA expression levels. Each sample was assayed in duplicate. All primer sets were tested to ensure
Immunoblot Analysis (Western Blotting)
Whole cell lysates were prepared by washing the cells twice with ice-cold PBS and then adding lysis buffer (50 mmol/L Tris-Cl, pH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Igepal Ca 630, 0.1% SDS, 0.5% SDC, protease inhibitor, phosphatase inhibitor cocktail I, phosphatase inhibitor cocktail II) to each well. The cells were collected in lysis buffer using a cell scraper, and the sample placed on ice and sonicated briefly. The protein content was measured using the Bio-Rad protein assay kit (Bio-Rad Laboratories).
Protein samples were heated in SDS Laemmli loading buffer (1:1 v/v) at 95 °C for 5 min, and total protein (40 μ g) was loaded onto a 7.5% SDS−polyacrylamide gel.
Electrophoresis was conducted at 100 V. The proteins were transferred overnight at 35
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Statistics
All studies were repeated at least three times. Descriptive statistics were performed for each data set. Graphs were plotted, data were transformed, and statistical analysis was carried out using GraphPad Prism 6.0 (GraphPad Software).
β -hCG concentrations were log transformed and analyzed using one-way ANOVA followed by Dunnett's post test. For expression studies, either unpaired Student's t test or one-way ANOVA followed by the Tukey's post test was performed as appropriate.
Differences in the cellular accumulation of fluorescent substrates were analyzed using a one-way ANOVA followed by Dunnett's post test. P value < 0.05 was considered to be significant.
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RESULTS
Differentiation of cytotrophoblasts in culture
We confirmed prior reports of cytotrophoblast morphological and biochemical differentiation in culture. The morphological changes were accompanied by biochemical differentiation as indicated by increased hCG secretion. Cytotrophoblast β -hCG secretion increased significantly by 72h and peaked at 96h in culture (Supplemental Figure 1) .
PGE 2 production by Jar cells and primary trophoblasts
To address the possible effect of endogenous PGE 2 produced in cell culture we evaluated PGE 2 concentrations in culture media from untreated cells. In a 24h culture, Jar cells (5 x 10 5 cells) produced a mean PGE 2 concentration of 39.7 ± 2.8 pg/ml (n=4).
The basal level of PGE 2 produced in 24h by differentiated trophoblasts (6 x 10 6 cells; cultured for 4 days) was 153.4 ± 23.4 pg/ml (n=5).
PGE 2 differentially affects BCRP expression in human placental cells
PGE 2 increased BCRP mRNA expression nearly 1.9-fold in Jar cells (P < 0.001) and 1.5-fold in human primary trophoblast (P < 0.05) after 24h treatment ( Figure 1A ).
PGE 2 decreased PGP mRNA in Jar cells by ~ 50% (P < 0.05) compared to control, but there was no change of expression in human trophoblasts ( Figure 1B ).
Compared to untreated control, 24h of PGE 2 produced a 3.3-fold (P < 0.01) increase in Jar cell BCRP protein and a 1.6-fold (P < 0.05) increase in human primary trophoblasts ( Figure 2A ). Pgp protein levels were not statistically altered among cells exposed to PGE 2 and vehicle (P = 0.29) ( Figure 2B ).
PGE 2 alters BCRP, but not Pgp activity DMD #59477
This article has not been copyedited and formatted. The final version may differ from this version. accumulation after 60min incubation in the presence of the BCRP selective blocker FTC (P < 0.05) ( Figure 3A ). In agreement with the increased BCRP mRNA and protein levels, PGE 2 treatment (5 μ g/ml; 24h) decreased the accumulation of Hoechst 33342
over 20% compared to control in Jar cells and around 16% in primary trophoblasts (P < 0.05; Figure 3A) . Accumulation of the Pgp substrate, calcein AM, was about 30%
higher in the presence of verapamil (P < 0.05; Figure 3B ), but there was no difference when cells were treated first with PGE 2 . Cells treated with MK 571 also increased cellular accumulation of calcein AM indicating the presence of MRP1 in Jar cells.
However, PGE 2 had no effect on MRP1 mRNA level as determined by qrt-PCR (Supplementary Figure 2A, B) . The treatment of Jar cells with verapamil also increased the cellular accumulation of Flutax-2 by 33% (P < 0.05). PGE 2 increased Flutax 12%, but this increase did not achieve statistical significance ( Figure 3B ).
PGE 2 regulates BCRP expression via EP1 and EP3 receptors
To determine the EP receptors involved in PGE 2 -mediated up-regulation of BCRP expression, cells were pretreated with an EP receptor antagonist before exposure to PGE 2 (5 µg/ml) for 24h. Both the selective EP1 antagonist SC-19220 (P < 0.05) and the EP3 antagonist L-798196 (P < 0.01) inhibited the induction of BCRP mRNA by PGE 2 . Treatment of cells with EP4 selective antagonist L-161982 and EP1/2 antagonist AH 6809 slightly reduced BCRP mRNA levels ( Figure 4) . All EP receptor antagonists tested failed to fully restore Pgp mRNA levels in Jar cells exposed to PGE 2 ( Figure 5 ). There was no effect on Pgp or BCRP expression when cells were treated
DMD #59477
This article has not been copyedited and formatted. The final version may differ from this version. with antagonist alone. It should be noted that neither PGE 2 nor the EP receptor antagonists altered EP1 and EP3 receptor levels (data not shown), indicating that the effect of these agents on transporter expression is not attributable to changes in the cellular expression of EP1 and EP3, but rather the signaling pathway involved.
Sulprostone (EP3 agonist; 10 μ M) increased BCRP mRNA expression in Jar cells 1.7-fold (P < 0.001) while 17-phenyltrinor PGE 2 (EP1 agonist; 10 μ M) increased BCRP expression 1.4-fold (P < 0.05; Figure 6 ).
PGE 2 stimulates AP-1 and represses NF-κB activation
To examine whether NF-κB and AP-1 mediate PGE 2 -induced BCRP expression in Jar cells, we first transfected the cells with NF-κB cis-reporter plasmid pNF-κB-Luc or AP-1 cis-reporter plasmid pAP-1-Luc. Once complete, PGE 2 treatment repressed NF-κ B activation as reflected in a nearly 2.0-fold decrease in luciferase activity at 24h (P < 0.001). AP-1 luciferase activity was increased 2.9-fold in the presence of PGE 2 at 24h (P < 0.001, Figure 7A ).
In subsequent experiments, inhibition of NF-κB and AP-1 with BAY-11-7082 (10 μ M) and SR 11302 (10 μ M), respectively, had little effect on PGE 2 -induced BCRP upregulation ( Figure 7B ). The addition of BAY 11-7082 or SR 11302 alone had no affect on BCRP mRNA levels (data not shown).
DISCUSSION
Inflammatory responses during pregnancy can trigger altered expression of placenta transporters, but the factors responsible for these changes remain largely unknown. We find that PGE 2 , an immunomodulatory lipid associated with the terminal
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This article has not been copyedited and formatted. The final version may differ from this version. Activation of COX-2 has also been shown to increase Pgp (Liu et al., 2010; Patel et al., 2002) . Thus, we were surprised that PGE 2 decreased mRNA levels of Pgp in Jar cells (Figure 1) . Though there was a trend toward decreased Pgp protein expression, the differences failed to achieve statistical significance (P = 0.29) ( Figure 2B ). As previously cited, differences at the RNA level do not always closely correlate with ABC protein expression in trophoblast cultures (Evseenko et al., 2006) . Furthermore, we found virtually no effect of PGE 2 on calcein AM accumulation in Jar cells. Calcein AM is also an MRP1 substrate, which too, is functionally expressed in Jar cells (Evseenko et al., 2007) . Although PGE 2 had no effect on MRP1 transcripts (Supplemental Figure   2B ), MRP1 inhibition with MK-571 increased the cellular accumulation of calcein AM (Supplemental Figure 2A) . Paclitaxel may be a better substrate for Pgp, even though it , 2006) . The choriocarcinoma Jar cell line has been used to study trophoblast biology and transport in vitro (Atkinson et al., 2003; Coles et al., 2009; Evseenko et al., 2006; Serrano et al., 2007) . We chose Jar for the present study because it expresses both Pgp and BCRP at levels detectable for quantitation and shows evidence of functional expression of these transporters.
The most prominent effect of PGE 2 on transporter expression was observed in the Jar cells. In order to more closely evaluate mechanism and identify clear differences, we performed the subsequent studies using these cells. There are several reasons the effect of PGE 2 on transporter expression was more prominent in Jar cells.
Differentiation (syncytialization) may explain some or all the observed differences between the two cell models. Jar cells proliferate in culture but do not spontaneously fuse, whereas trophoblast cells form differentiated syncytium by days 4-5. β -hCG is produced by terminally differentiated syncytiotrophoblast and used to assess
This article has not been copyedited and formatted. The final version may differ from this version. cytotrophoblast biochemical differentiation in culture. We found that β -hCG levels dramatically increase around 72h in culture (Supplemental Figure 1) . BCRP and Pgp expression appear to change as trophoblasts mature in culture. BCRP levels in primary trophoblasts increased at 120h of incubation relative to those at 24h, while P-gp decreased (Evseenko et al., 2006) . Even so, our results were similar for trophoblasts cultured for 1 day (data not shown) or 4-5 days prior to PGE 2 treatment.
Intrinsic differences in the functional expression of the PGE 2 machinery (i.e.
COX-2, AA, EP receptors, etc.) and PGE 2 production could also explain observed differences between the cells. For instance, previous reports failed to detect the production of PGE 2 by JEG-3 choriocarcinoma cells. In contrast to primary trophoblasts, it has been suggested that the limited arachidonate releasing capacity of JEG-3 cells might be responsible for the low PGE 2 production (Premyslova et al., 2006) .
In theory, this could mean that choriocarcinoma cells, such as Jar, are more sensitive to exogenous PGE 2 stimulation compared to the primary trophoblasts. In the present study, we determined that primary trophoblasts seeded at a density of 6 x10 6 cells and differentiated for 4 days produced around 153.4 ± 23.4 pg/ml of PGE 2 in 24 h. Jar cells were also capable of producing PGE 2 . The mean basal concentration of PGE 2 produced in Jar cells seeded at a density of 5 x10 5 cells was 39.7 ± 2.8 pg/ml. We cannot rule out the possibility that endogenous PGE 2 may have some effect on transporter expression.
A primary function of BCRP and Pgp is to transport compounds out of placental cells and prevent access to the fetal circulation. In tissue barriers, BCRP and Pgp often act in concert (de Vries et al., 2007) , implying the loss of either transporter alone does not result in an appreciable increase in penetration of dual substrates. For example, in
This article has not been copyedited and formatted. The final version may differ from this version. Pgpa/b knockout mice (where bcrp1 is present) bcrp1 alone is sufficient to limit brain uptake of xenobiotics (Agarwal et al., 2011) . The same can be said of mdr1a/b in bcrp1 knockout mice. Thus, the greatest impact on transplacental passage of dual substrates may be seen when both transporters are similarly altered or when one of these transporters is predominately expressed in the cell.
BCRP mRNA levels are highest in placenta compared to other tissues, and it is approximately 10 times greater than Pgp in human term placenta {Ceckova, 2006 #29}.
Many drugs commonly administered to pregnant women such as glyburide (Zhou et al., 2008) , nitrofurantoin , and cimetidine (Pavek et al., 2005) Interestingly, Yeboah et al. (Yeboah et al., 2006) found that neither umbilical cord vein nor arteries express BCRP. They speculated that BCRP expression in the fetal blood vessel endothelial cells may be regulated by the local action of factors derived from the placenta itself. PGE 2 is produced by the placenta and our data links PGE 2 to upregulation of BCRP, advocating it as a potentially important factor in terms of placental transport.
The heterogeneity of PGE 2 immunoregulatory effects may depend on distinctive signaling mechanisms mediated by different PGE 2 receptors. All 4 membrane receptor
This article has not been copyedited and formatted. The final version may differ from this version. subtypes (EP1-4) have been localized in human placental villous tissue (Grigsby et al., 2006) . It is believed their presence in human placenta may indicate autocrine and paracrine roles for PGE 2 in the signaling pathways associated with parturition (Grigsby et al., 2006) . We suspect that specific EP receptors are involved in downstream regulation of BCRP and Pgp. We observed that antagonism of the EP1 and EP3
receptors counteracts the increase in BCRP mRNA induced by PGE 2 (Figure 4) , and that the EP1 and EP3 agonists alone increased BCRP mRNA expression ( Figure 6 ).
Thus, EP1/3 receptors may facilitate PGE 2 signals that modulate placental BCRP expression. Further evaluation may reveal that these receptors are potential pharmacological targets, whereby limiting the responsiveness to PGE 2 during pathologic pregnancy could potentially mitigate BCRP over-expression while maintaining its relevant transport function. This could allow adequate delivery of drugs intended for the fetus without compromising the protective function of BCRP in the placenta.
The greatest impact on BCRP mRNA expression occurred with the EP3 receptor.
This receptor is unique among the EP subtypes in that it seems to be the only prostanoid receptor present in the syncytiotrophoblast layer of placenta from women at various stages of labor (Grigsby et al., 2006) . Its expression corresponds to the apical membrane localization of BCRP in syncytiotrophoblasts, supporting its potential involvement in BCRP regulation. The EP3 receptor has multiple isoforms generated by alternative splicing. These variants differ in tissue expression, constitutive activity, and regulation of signaling molecules (Adam et al., 1994; Negishi et al., 1995; Schmid et al., 1995) . Their expression profile in the human placenta is unknown, but suggests the
This article has not been copyedited and formatted. The final version may differ from this version. receptor signaling produces dose dependent changes in the activity of NF-κB (Hu et al., 2008) . Others have observed that NF-κB inhibits the transcription of Pgp/mdr1a/b (Ogretmen and Safa, 1999) and induces the transcription of BCRP/Bcrp1 (Pradhan et al., 2010) . We found that PGE 2 decreased NF-κB and increased AP-1 activity ( Figure   7A ) in Jar cells, supporting AP-1 activation as a candidate transcriptional pathway for BCRP up-regulation. It is possible that NF-κB and AP-1 may modulate each other and that activation of AP-1 negatively affects NF-κB activity (Fujioka et al., 2004) . While this could explain the effect of PGE 2 on NF-κB activity, inhibition of these transcription factors in PGE 2 -treated Jar cells did not interfere with BCRP induction ( Figure 7B ). This indicates that BCRP mRNA may not be directly regulated by NF-κB or AP-1 when stimulated with PGE 2 . Clearly, a broader investigation into the transcription factor profile activated by PGE 2 stimulation would provide insight into those that contribute to the induction of BCRP mRNA.
Both BCRP and Pgp are important elements of barrier function and distinct signaling pathways may regulate their functional expression. This study highlights a
